High-resolution genotyping of the endemic Salmonella Typhi population during a Vi (typhoid) vaccination trial in Kolkata.

Authors:
Address: Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia. kholt@unimelb.edu.au
Journal:


Publication:
Free Text: High-resolution genotyping of the endemic Salmonella Typhi population during a Vi (typhoid) vaccination trial in Kolkata.

abstract

BACKGROUND:

typhoid fever, caused by Salmonella enterica serovar Typhi (S. Typhi), is a major health problem especially in developing countries. Vaccines against typhoid are commonly used by travelers but less so by residents of endemic areas.

METHODOLOGY:

We used single nucleotide polymorphism (SNP) typing to investigate the population structure of 372 S. Typhi isolated during a typhoid disease burden study and Vi vaccine trial in Kolkata, India. Approximately sixty thousand people were enrolled for fever surveillance for 19 months prior to, and 24 months following, Vi vaccination of one third of the study population (May 2003-December 2006, vaccinations given December 2004).

PRINCIPAL FINDINGS:

A diverse S. Typhi population was detected, including 21 haplotypes. The most common were of the H58 haplogroup (69%), which included all multidrug resistant isolates (defined as resistance to chloramphenicol, ampicillin and co-trimoxazole). Quinolone resistance was particularly High among H58-G isolates (97% Nalidixic acid resistant, 30% with reduced susceptibility to ciprofloxacin). Multiple typhoid fever episodes were detected in 22 households, however household clustering was not associated with specific S. Typhi haplotypes.

CONCLUSIONS:

Typhoid fever in Kolkata is caused by a diverse population of S. Typhi, however H58 haplotypes dominate and are associated with multidrug and quinolone resistance. Vi vaccination did not obviously impact on the haplotype population structure of the S. Typhi circulating during the study period.



Related Articles
Typhoid in Kenya is associated with a dominant multidrug-resistant Salmonella enterica serovar Typhi haplotype that is also widespread in Southeast Asia.
J Clin Microbiol. 2010
Typhoid in Kenya is associated with a dominant multidrug-resistant Salmonella enterica serovar Typhi haplotype that is also widespread in Southeast Asia.
Kariuki S, Revathi G, Kiiru J, Mengo DM, Mwituria J, Muyodi J, Munyalo A, Teo YY, Holt KE, Kingsley RA, et al. J Clin Microbiol. 2010 Jun; 48(6):2171-6. Epub 2010 Apr 14.
High-throughput bacterial SNP typing identifies distinct clusters of Salmonella Typhi causing typhoid in Nepalese children.
BMC Infect Dis. 2010
High-throughput bacterial SNP typing identifies distinct clusters of Salmonella Typhi causing typhoid in Nepalese children.
Holt KE, Baker S, Dongol S, Basnyat B, Adhikari N, Thorson S, Pulickal AS, Song Y, Parkhill J, Farrar JJ, et al. BMC Infect Dis. 2010 May 31; 10:144. Epub 2010 May 31.
Antimicrobial susceptibility of Salmonella Typhi in India.
J Infect Dev Ctries. 2010
Antimicrobial susceptibility of Salmonella Typhi in India.
Nagshetty K, Channappa ST, Gaddad SM. J Infect Dev Ctries. 2010 Mar 8; 4(2):70-3. Epub 2010 Mar 8.
Review Population impact of Vi capsular polysaccharide vaccine.
Expert Rev Vaccines. 2010
Review Population impact of Vi capsular polysaccharide vaccine.
Khan MI, Ochiai RL, Clemens JD. Expert Rev Vaccines. 2010 May; 9(5):485-96.
Review Multidrug-resistant typhoid fever: a review.
J Infect Dev Ctries. 2011
Review Multidrug-resistant typhoid fever: a review.
Zaki SA, Karande S. J Infect Dev Ctries. 2011 May 28; 5(5):324-37. Epub 2011 May 28.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.